Tiny lab-made proteins ‘hold great promise’ to treat Alzheimer’s, scientists say
New study represents ‘significant leap forward’ and provides ‘potent therapeutic strategy,’ scientists say
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A breakthrough with a new class of lab-made proteins “holds great promise” in enhancing the body’s defence against neurodegenerative conditions like Alzheimer’s disease, according to a new study.
These lab-made protein polymers can enhance the body’s antioxidant response, known to be crucial for protection against many debilitating neurodegenerative diseases like Alzheimer’s, Parkinson’s, and the muscle-wasting condition amyotrophic lateral sclerosis (ALS), scientists say.
A common thread connecting these diseases is the accumulation of highly reactive ions and chemicals within cells, adding stress to tissues and organs.
The body’s natural antioxidant response is known to be key for protection against what is known as oxidative stress, a factor in many neurodegenerative diseases.
In the latest research, scientists targeted the interaction between two proteins Keap1/Nrf2, which plays a role in the body’s antioxidant response.
Scientists developed a synthetic protein in the lab that inhibited Nrf2’s interaction with Keap1, a process they say can mitigate damage in such debilitating conditions.
“We established Nrf2 as a principal target for the treatment of neurodegenerative diseases over the past two decades, but this novel approach for activating the pathway holds great promise to develop disease-modifying therapies,” study co-author Jeffrey Johnson from the University of Wisconsin-Madison said.
Until now, conventional treatments using these kinds of synthetic small proteins have fallen short due to the lack of stability of these molecules and their uptake within cells.
Researchers now developed these small polymers to mimic the body’s natural proteins, ensuring they penetrate within cells, remain stable, and resist being broken down.
They say this new approach to inhibit the Keap1/Nrf2 interaction “represents a significant leap forward” that can enhance the body’s antioxidant response and provide a “potent therapeutic strategy.”
“Through modern polymer chemistry, we can begin to think about mimicking complex proteins,” Nathan Gianneschi, another author of the study, said.
“The promise lies in the development of a new modality for the design of therapeutics. This could be a way to address diseases like Alzheimer’s and Parkinson’s among others where traditional approaches have struggled,” Dr Gianneschi said.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments